NZ pharmaceuticals producer deepens US links
One of New Zealand’s leading medicinal cannabis companies has announced a second distribution agreement to the United States.
Nubu Pharmaceuticals now has two deals with the first being with MGC Pharmaceuticals Ltd, a European cannabis-based biopharma company supplying GMP Phytocannabinoid-derived medicines to patients globally.
The second deal is with the USbased, global medicinal cannabis manufacturer and distributor Plants Not Pills (PNP), Nubu announced yesterday.
The global medicinal cannabis market is estimated to be worth over $100 billion by 2026.
Nubu’s CEO Mark Dye, a former television and Newstalk ZB presenter, said the distribution agreements with MGC & PNP were an exciting development in the growth phase of the business.
“Nubu is now one of the largest New Zealand-based medicinal cannabis companies [in terms of patient numbers], and continuing to build a robust network of key partners, like MGC, will not only see revenue increase, but also help satisfy existing and future demand.”
Partnering with MGC, he added, will bring many other additional benefits.
“MGC collaborates extensively with the world’s best universities and companies to undertake extensive research and development. Most exciting is their current research in neurological disorders, but they are also researching everything from cancer treatment through to autoimmune diseases. We are delighted to be working with MGC.”